Ascendis Pharma Presents HighLiGHts Phase 3 Trial Design for Lonapegsomatropin (TransCon hGH) Across Four Pediatric Short-Stature Indications at ESPE 2026 Closing Day
Ascendis Pharma A/S (NASDAQ: ASND) presented Thursday September 10, 2026 at the closing day of the ESPE 2026 congress in Marseille the trial-design abstract for HighLiGHts, a Phase 3 study of lonapegsomatropin (TransCon human growth hormone, a sustained-release growth hormone prodrug branded SKYTROFA in the U.S. and marketed for pediatric growth hormone deficiency since 2021) in children with short stature or growth failure due to Turner syndrome, SHOX deficiency, small-for-gestational-age (SGA), or idiopathic short stature. The four-indication combined trial design targets patients whose short stature is not attributable to growth hormone deficiency per se, expanding beyond the current SKYTROFA U.S. label for pediatric GHD. The presentation was one of several Ascendis ESPE items following the Tuesday September 8 podium delivery of first Week 52 sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP) in infants with achondroplasia. Ascendis reported €55 million in Q2 2026 SKYTROFA revenue alongside €252 million from YORVIPATH and €8 million from YUVIWEL, for a €315 million combined product-revenue quarter.